Q-omics provides the consensus-scored PCDH19 profile across patient tissues and cancer cell-line models. PCDH19 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PCDH19 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, PCDH19 RNA expression shows 21,347 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, KIRP, and HNSC as cancer lineages where PCDH19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH19 survival associations across molecular data types. PCDH19 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH19 RNA expression–survival associations across cancer types. High PCDH19 expression shows unfavorable associations in THCA and COAD, but favorable associations in KIRC, BRCA, LUSC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PCDH19 RNA expression.
This table summarizes PCDH19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PCDH19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH19 shows lower tumor expression in KIRP, BLCA, BRCA and KICH and higher tumor expression in LUSC and UCEC. The KIRP box plot shows higher PCDH19 RNA expression in normal versus tumor tissue (log2 FC = −0.276, t-test p < 0.001).
This table shows molecular features associated with PCDH19 in patient tissues and cancer cell lines. In patient samples, PCDH19 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDH19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
